Theratechnologies (TH) has received a rating update from a Wall Street analyst today. RBC Capital’s analyst Brian Abrahams reiterates their Hold rating on the shares, with a C$8 price target.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 7.5% and a 52.9% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Theratechnologies with a C$11.60 average price target.
Theratechnologies’ market cap is currently C$529.1M and has a P/E ratio of 0. The company has a Price to Book ratio of 11.77.
Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). It offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
The company’s shares closed on Wednesday at C$6.71.
